Don L. Gibbons

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

81h-index23.4kcitations1.1kworks2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(351), Cancer Immunotherapy and Biomarkers(323), Cancer Genomics and Diagnostics(170), Lung Cancer Research Studies(166), RNA modifications and cancer(162)

Publications1.1k total

Spatial Profiling Reveals Distinct Molecular and Immune Evolution of Mouse Lung Adenocarcinoma Precancers with or Without Carcinogen Exposure
Advanced Science·2026Open Access
PDK1 and YAP1/TEAD signaling drive acquired KRAS inhibitor resistance in KRAS-mutant non-small cell lung cancer
2025Open Access
Supp Fig 7 from <i>ATM</i> Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
2025Open Access
Supp Table 5 from <i>ATM</i> Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
2025Open Access
Supp Fig 9 from <i>ATM</i> Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
2025Open Access
Supp Table 3 from <i>ATM</i> Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
2025Open Access
Supp Table 4 from <i>ATM</i> Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
2025Open Access
Development of PET/CT-clinical nomograms for predicting lymph node metastasis in primary lung cancer
European Radiology·2025Open Access
Supplementary Figure S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S3 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S8 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S1 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S1 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S3 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S4 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S4 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S9 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S5 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S7 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S2 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
page 1 of 57Next →

Frequent Co-authors

John V. Heymach(28), Ignacio I. Wistuba(24), Lauren A. Byers(17), Edwin R. Parra(15), J. Jack Lee(14), Ferdinandos Skoulidis(12), Stephen G. Swisher(12), Jing Wang(12), Boris Sepesi(10), Chad J. Creighton(10), Carmen Behrens(10), Lixia Diao(9), Junya Fujimoto(9), Tina Cascone(9), Jianjun Zhang(8), Anne S. Tsao(8), Jonathan M. Kurie(8), Jaime Rodriguez‐Canales(8), Young‐Ho Ahn(7), David H. Peng(7)